Estimating medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders

Psychiatric Services

Volumn 58, Issue 10, 2007, Pages 1285-1291

  Donohue, Julie Marie ^a   Frank, Richard Gabriel ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; ESCITALOPRAM; GENERIC DRUG; LAMOTRIGINE; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROCHLORPERAZINE MALEATE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; COST CONTROL; DRUG COST; DRUG FORMULARY; DRUG PROGRAM; DRUG UTILIZATION; FEMALE; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL DISEASE; PATIENT COUNSELING; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; UTILIZATION REVIEW;

EID: 35748964996     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.10.1285     Document Type: Article

References (28)

1. Zuvekas SH: Prescription drugs and the changing patterns of treatment for mental disorders 1996-2001. Health Affairs 24:195-205, 2005
2. Frank RG, Conti RM, Goldman HH: Mental health policy and psychotropic drugs. The Milbank Quarterly 83:271-298, 2005
3. Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps. Menlo Park, Calif, Kaiser Family Foundation, 2004
4. Duggan M: Do new prescription drugs pay for themselves? The case of second generation antipsychotics. Journal of Health Economics 24:1-31, 2005
5. Baugh DK, Pine PL, Blackwell S, et al: Medicaid spending and utilization for central nervous system drugs. Health Care Financing Review 26:57-73, 2004
6. Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Affairs 24:536-544, 2005
7. Donohue JM: Mental health in the Medicare drug benefit: a new regulatory model? Health Affairs 25:707-719, 2006
8. Report to the Congress: Increasing the Value of Medicare. Washington, DC, Medicare Payment Advisory Commission, 2006
9. Morden NE, Garrison LP: Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Affairs 25:491-500, 2006
10. Prescription Drug Coverage Among Medicare Beneficiaries. Menlo Park, Calif, Kaiser Family Foundation, 2006
11. Hoadley J: The Effect of Formularies and Other Cost Management Tools on Access to Medications: An Analysis of the MMA and Proposed Regulations. Menlo Park, Calif, Kaiser Family Foundation, 2004
12. Medicare Modernization Act Final Guidelines - Formularies: CMS Strategy for Affordable Access to Comprehensive Drug Coverage. Baltimore, Centers for Medicare and Medicaid Services, 2005
13. An In-depth Examination of Formularies and Other Features of Medicare Drug Plans. Menlo Park, Calif, Kaiser Family Foundation, 2006
14. McCombs JS, Shi L, Stimmel GL, et al: A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clinical Therapeutics 24:1939-1959, 2002
15. Fischer MA, Schneeweiss S, Avorn J, et al: Medicaid prior authorization programs and the use of cyclooxygenase-2 inhibitors. New England Journal of Medicine 351:2187-2194, 2004
16. Roughead EE, Zhang F, Ross-Degnan D, et al: Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Medical Care 44:378-382, 2006
17. Smalley WE, Griffin MR, Fought RL, et al: Effect of a prior authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. New England Journal of Medicine 332:1612-1617, 1995
18. Delate T, Mager DE, Sheth J, et al: Clinical and financial outcomes associated with a proton pump inhibitor prior authorization program in a Medicaid population. American Journal of Managed Care 11:29-36, 2005
19. Hartung DM, Touchette DR, Ketchum KL, et al: Effects of a prior authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clinical Therapeutics 26:1518-1532, 2004
20. West JC, Wilk JE, Muszynski IL, et al: Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. American Journal of Psychiatry 164:789-796, 2007
21. Peters C: Medicare Advantage SNPs: A New Opportunity for Integrated Care? Washington DC, National Health Policy Forum, 2005
22. Verdier JM, Au M: Medicare Advantage Special Needs Plans Site Visits. Edited by Mathematica Policy Research. Washington, DC, MedPAC, 2006
23. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331:650-655, 1994
24. LaPensee KT: Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. Journal of Managed Care Pharmacy 9:36-44, 2003
25. Huskamp HA: Managing psychotropic drug costs: will formularies work? Health Affairs 22(5):84-96, 2003
26. Goldman DP, Joyce GE, Escarce J, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:2344-2350, 2004
27. Cubanski J, Newman P: Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Affairs Web Exclusive, Nov 2006, W1-W12
28. Huskamp HA, Stevenson D, Donohue JM, et al: Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatric Services 58:308-310, 2007